Neurological manifestations with jugular vein thrombosis linked to an inflammatory profile may be a sequela of long COVID
Abstract More than 670 million cases of coronavirus disease 2019 (COVID‐19) have been recorded worldwide in the 3 years since the start of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic. About 45% of survivors of COVID‐19 develop a syndrome known as long‐term COVID, in whi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Neuroprotection |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/nep3.24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850099530112958464 |
|---|---|
| author | Elizabeth Mendoza‐Portillo Estefania Aleman‐Navarro G. Aleph Prieto Yvonne Rosenstein Jose J. Lozano‐Nuevo Araceli Perez‐Lopez |
| author_facet | Elizabeth Mendoza‐Portillo Estefania Aleman‐Navarro G. Aleph Prieto Yvonne Rosenstein Jose J. Lozano‐Nuevo Araceli Perez‐Lopez |
| author_sort | Elizabeth Mendoza‐Portillo |
| collection | DOAJ |
| description | Abstract More than 670 million cases of coronavirus disease 2019 (COVID‐19) have been recorded worldwide in the 3 years since the start of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic. About 45% of survivors of COVID‐19 develop a syndrome known as long‐term COVID, in which symptoms persist even months after the acute infection. About 76% of patients with long COVID experience neurological manifestations. Moreover, patients who have survived COVID‐19 have an increased risk of cerebral venous thrombosis. This case report describes a 41‐year‐old woman who developed neurological manifestations associated with jugular vein thrombosis 24 h after administration of the Oxford–AstraZeneca (ChAdOx1 nCoV‐19) vaccine (AstraZeneca‐Serum Institute of India). She had been infected with SARS‐CoV‐2 three months before vaccination. Although initially suspected to be a case of vaccine‐induced immune thrombotic thrombocytopenia (VITT) in view of her recent vaccination, the patient did not have any hallmarks of VITT, such as thrombocytopenia, an increased d‐dimer level, or antibodies against platelet factor‐4. Moreover, the neurological manifestations were associated with a high concentration of inflammatory cytokines, including interleukin (IL)‐6, IL‐17A, and IL‐21, and elevated neutrophil levels in cerebrospinal fluid, suggesting that inflammatory immune components had a role in the development of thrombotic events and pointing to an alternative diagnosis. In this case, the laboratory results indicated that the neurological manifestations associated with jugular vein thrombosis were not associated with VITT. Therefore, we propose that the thrombosis of the left jugular vein was a sequela of SARS‐CoV‐2 infection. |
| format | Article |
| id | doaj-art-1d73db2ae4424dbe8d5351d73ddbd262 |
| institution | DOAJ |
| issn | 2770-7296 2770-730X |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neuroprotection |
| spelling | doaj-art-1d73db2ae4424dbe8d5351d73ddbd2622025-08-20T02:40:29ZengWileyNeuroprotection2770-72962770-730X2023-12-011217017510.1002/nep3.24Neurological manifestations with jugular vein thrombosis linked to an inflammatory profile may be a sequela of long COVIDElizabeth Mendoza‐Portillo0Estefania Aleman‐Navarro1G. Aleph Prieto2Yvonne Rosenstein3Jose J. Lozano‐Nuevo4Araceli Perez‐Lopez5Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez Ciudad de México MéxicoInstituto de Biotecnología Universidad Nacional Autónoma de México (UNAM) Cuernavaca Morelos MéxicoInstituto de Neurobiología UNAM‐Juriquilla Querétaro MéxicoInstituto de Biotecnología Universidad Nacional Autónoma de México (UNAM) Cuernavaca Morelos MéxicoHospital General de Ticomán Secretaría de Salud de la Ciudad de México Ciudad de México MéxicoUnidad de Investigación en Biomedicina Facultad de Estudios Superiores Iztacala, UNAM Tlalneplantla Estado de México MéxicoAbstract More than 670 million cases of coronavirus disease 2019 (COVID‐19) have been recorded worldwide in the 3 years since the start of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic. About 45% of survivors of COVID‐19 develop a syndrome known as long‐term COVID, in which symptoms persist even months after the acute infection. About 76% of patients with long COVID experience neurological manifestations. Moreover, patients who have survived COVID‐19 have an increased risk of cerebral venous thrombosis. This case report describes a 41‐year‐old woman who developed neurological manifestations associated with jugular vein thrombosis 24 h after administration of the Oxford–AstraZeneca (ChAdOx1 nCoV‐19) vaccine (AstraZeneca‐Serum Institute of India). She had been infected with SARS‐CoV‐2 three months before vaccination. Although initially suspected to be a case of vaccine‐induced immune thrombotic thrombocytopenia (VITT) in view of her recent vaccination, the patient did not have any hallmarks of VITT, such as thrombocytopenia, an increased d‐dimer level, or antibodies against platelet factor‐4. Moreover, the neurological manifestations were associated with a high concentration of inflammatory cytokines, including interleukin (IL)‐6, IL‐17A, and IL‐21, and elevated neutrophil levels in cerebrospinal fluid, suggesting that inflammatory immune components had a role in the development of thrombotic events and pointing to an alternative diagnosis. In this case, the laboratory results indicated that the neurological manifestations associated with jugular vein thrombosis were not associated with VITT. Therefore, we propose that the thrombosis of the left jugular vein was a sequela of SARS‐CoV‐2 infection.https://doi.org/10.1002/nep3.24cerebral venous thrombosislong COVIDvaccine |
| spellingShingle | Elizabeth Mendoza‐Portillo Estefania Aleman‐Navarro G. Aleph Prieto Yvonne Rosenstein Jose J. Lozano‐Nuevo Araceli Perez‐Lopez Neurological manifestations with jugular vein thrombosis linked to an inflammatory profile may be a sequela of long COVID Neuroprotection cerebral venous thrombosis long COVID vaccine |
| title | Neurological manifestations with jugular vein thrombosis linked to an inflammatory profile may be a sequela of long COVID |
| title_full | Neurological manifestations with jugular vein thrombosis linked to an inflammatory profile may be a sequela of long COVID |
| title_fullStr | Neurological manifestations with jugular vein thrombosis linked to an inflammatory profile may be a sequela of long COVID |
| title_full_unstemmed | Neurological manifestations with jugular vein thrombosis linked to an inflammatory profile may be a sequela of long COVID |
| title_short | Neurological manifestations with jugular vein thrombosis linked to an inflammatory profile may be a sequela of long COVID |
| title_sort | neurological manifestations with jugular vein thrombosis linked to an inflammatory profile may be a sequela of long covid |
| topic | cerebral venous thrombosis long COVID vaccine |
| url | https://doi.org/10.1002/nep3.24 |
| work_keys_str_mv | AT elizabethmendozaportillo neurologicalmanifestationswithjugularveinthrombosislinkedtoaninflammatoryprofilemaybeasequelaoflongcovid AT estefaniaalemannavarro neurologicalmanifestationswithjugularveinthrombosislinkedtoaninflammatoryprofilemaybeasequelaoflongcovid AT galephprieto neurologicalmanifestationswithjugularveinthrombosislinkedtoaninflammatoryprofilemaybeasequelaoflongcovid AT yvonnerosenstein neurologicalmanifestationswithjugularveinthrombosislinkedtoaninflammatoryprofilemaybeasequelaoflongcovid AT josejlozanonuevo neurologicalmanifestationswithjugularveinthrombosislinkedtoaninflammatoryprofilemaybeasequelaoflongcovid AT araceliperezlopez neurologicalmanifestationswithjugularveinthrombosislinkedtoaninflammatoryprofilemaybeasequelaoflongcovid |